Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Larazotide - Alba Therapeutics/Innovate Biopharmaceuticals

Drug Profile

Larazotide - Alba Therapeutics/Innovate Biopharmaceuticals

Alternative Names: AT-1001 - Alba Therapeutics; INN-202; INN-217; INN-289; Larazotide acetate; SPD 550

Latest Information Update: 26 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Maryland School of Medicine
  • Developer Alba Therapeutics; Alba Therapeutics Corporation; Innovate Biopharmaceuticals; Teva Pharmaceutical Industries; University of Virginia School of Medicine
  • Class Anti-inflammatories; Antihyperglycaemics; Hepatoprotectants; Oligopeptides
  • Mechanism of Action Cell membrane permeability inhibitors; Myosin-light-chain kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Coeliac disease; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase III Coeliac disease
  • Phase I Crohn's disease
  • Preclinical Non-alcoholic steatohepatitis
  • Research Gastrointestinal disorders
  • No development reported Irritable bowel syndrome
  • Discontinued Type 1 diabetes mellitus

Most Recent Events

  • 26 Jun 2019 Larazotide is available for licensing in (excluding USA) as of 25 Jun 2019
  • 10 Jun 2019 Phase-III clinical trials in Coeliac disease in USA (PO) (NCT03569007)
  • 10 Jun 2019 Innovate Biopharmaceuticals plans phase III trials for Coeliac disease (PO) in the second quarter of 2019 (PO, Capsule) (NCT03569007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top